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[57] ABSTRACT 
Nicotine analogs that have nicotinic receptor antagonist 
properties. These compounds have been shown to competi 
tively inhibit dopamine release induced by nicotine. The 
nicotine analog compounds are useful in the treatment of 
nicotine abuse, smoking cessation therapy, as an antidote for 
nicotine intoxication, treatment of cognitive disorders such 
as Alzheimer’s disease and for the treatment of Parkinson’s 
disease. 
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NICOTINIC RECEPTOR ANTAGONISTS IN 
THE TREATMENT OF 
NEUROPHARMACOLOGICAL DISORDERS 
FIELD OF THE INVENTION 
This invention relates to nicotine analogs that have nico 
tinic receptor antagonist properties. The analog compounds 
are shown to competitively inhibit dopamine release induced 
by nicotine. The nicotine analog compounds are useful in the 
treatment of nicotine abuse, smoking cessation therapy, as 
an antidote for nicotine intoxication, treatment of cognitive 
disorders such as Alzheirner’s disease and for the treatment 
of Parkinson’s disease. 
BACKGROUND 
The structure-activity relationship (SAR) of antagonist 
molecules at neuronal nicotinic receptors have not been 
systematically investigated. From the work that has been 
reported, there appears to be far less correlation of structure 
and function with antagonists than is observed with agonist 
molecules (Barlow and Johnson, 1989a,b; Bears and Reich, 
1970; Pauling and Petcher, 1973; Sheridan et al. 1986, 1987; 
Wasserman et al. 1979). Due the diverse structures of 
antagonist molecules, it is di?icult to propose a common 
antagonist binding site or pharmacophore for receptor 
antagonists such as lobeline, DHBI, neuronal bungarotoxin 
and strychnine. Thus, it is possible that the noncorrelation of 
structure and function of antagonists may re?ect an antago 
nism at di?erent nicotinic receptor subtypes requiring spe 
ci?c three dimensional antagonist pharrnacophores. 
Sheridan (1989) proposed that antagonists compete for 
the same binding site as agonists; however, antagonists may 
not bind in the same way as agonists. Furthermore, agonists 
and antagonists may bind differently to di?erent quaternary 
states of the receptor protein. However, it is presumed likely 
from the data available that both agonists and antagonists are 
recognized by the anionic and donor groups in the binding 
site. One must assure that some property other than phar 
macophore geometry must be important for antagonism. 
Sheridan et a1. (1989) suggested that to be an agonist, a 
molecule must not only be able to achieve the pharmacoph 
ore geometry, but must also be con?ned to a speci?c volume. 
Nicotine compounds and derivatives are known. For 
example, U.S. Pat. No. 4,965,074 to Leeson discloses a 
method for the treatment of memory impairment, especially 
senile dementia of the Alzheimer's type. Nicotine is one 
compound. 
U.S. Pat. No. 5,227,391 to Caldwell et al. discloses a 
method of treating neuro-degenerative diseases by admin 
istering an effective amount of R(+) nicotine. U.S. Pat. No. 
5,272,155 to Arneric et al. discloses a (+)2-methylpiperidine 
which is a speci?c modulator of the neuronal nicotinic 
cholinergic receptor and which is useful in the treatment and 
prevention of cognitive, neurological and mental disorders. 
U.S. Pat. No. 5,278,176 to Lin discloses selective potent 
nicotinic agonists which are useful in the treatment of 
dementias, attentional hyperactivity disorder, anxiety asso 
ciated with cognitive impairment, or substance abuse with 
drawal. U.S. Pat. No. 5,276,043 to Lippiello et al. discloses 
treatment of patients suffering from negrodegenerative dis 
eases with an effective amount of an unsaturated nicotine 
compound Alzheimer’s disease and Parkinson’s disease are 
speci?cally mentioned as neurodegenerative disorders. 
U.S. Pat. No. 5,371,188 to Heinemann et al. discloses a 
family of neuronal nicotinic acetylcholine receptor subunit 
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compositions. U.S. Pat No. 5,369,028 to Harpold et al. 
discloses human neuronal nicotinic acetylcholine receptor 
subunits. 
U.S. Pat. No. 5,362,496 to Baker et al. discloses amethod 
for treating conditions responsive to nicotine therapy, and 
for cessation of smoking therapy, by transmucosal admin 
istration of nicotine to a patient. 
U.S. Pat. No. 5,316,759 to Rose et al. discloses a method 
of treating and reducing a drug dependency such as a 
nicotine dependency. The method involves administering 
nicotine in an amount that would normally provide the 
desired pharmacologic effects at a sustained level to partially 
saturate the receptors in the subject to whom nicotine is 
administered. An mecamylarnine is administered to block 
the pharrnacologic effects of the nicotine. 
U.S. Pat. No. 5,298,257 to Bannon et al. discloses a 
method of treating withdrawal symptoms associated with 
smoking cessation with transdermal delivery of nicotine. 
U.S. Pat. No. 5,232,933 to Lippiello et al. discloses 
treating neurodegenerative diseases with an eifective 
amount of an alpha-nicotine type compound. 
U.S. Pat. No. 5,187,169 to Lippiello et al. discloses 
methods of treating neurodegenerative disorders such as 
Alzheimer‘s disease and Parkinson’s disease with an effec 
tive amount of a cotinine compound 
U.S. Pat. No. 5,069,904 to Masterson discloses a method 
of using nicotine in the treatment of conditions susceptible 
to such treatment. Such conditions include disease states 
characterized by reduced central cholinergic function. Nico 
tine is administered to the subject until a therapeutic dose is 
achieved. 
NeumReport, Vol. 3, No. 12, pp. 1117-1120, December 
1992, discloses chronic nicotine treatment decreases dopam 
ine 2 agonist binding in rat basil ganglia. 
The European Journal of Pharmacology, Vol. 173, No. 1, 
pp. 93-108, Nov. 28, 1989, set out to determine whether 
N-methylcarbicol acts as an agonist or antagonist at nicotine 
and/or mnscarinic receptor sites. Nicotine stimulates the 
release of [3H]dopamine from rat striatal synaptosomes 
pre-loaded with dopamine. 
The Journal of Neurochemistry, Vol. 46, No. 4, pp. 
1109-17, April 1986 discloses that acetylcholine and nico 
tine accelerated the basil out?ow of gamma-arninobutyric 
acid (GABA) from rabbit caudate nucleus. ‘The ?ndings 
indicate that the GABA neurons and the caudate nucleus 
may be stimulated by dopamine and stimulated by acetyl 
choline via a nicotine receptor. 
The Journal of Neurochemistry, Vol. 40, No. 4, pp. 
1106-9, April 1983 disclosesthat tetrodotoxin-sensitive Na+ 
channels block nicotine transmission, possibly by noncom 
petitively inhibiting the interaction of nicotine with the 
receptor binding site. 
Biochemishy, Vol. 19, No. 12, pp. 2770-9, Jun. 10, 1980, 
describes the quantitative analysis of nicotine acetylcholine 
receptor function in torpedo postsynaptic membranes. 
Biochemistry Soc. Symp., Vol. 59, pp. 83-95, 1993 , 
discloses a view among researchers and clinicians that 
habitual cigarette smoking is a form of dependence on 
nicotine. It is the central action of nicotine that appears to be 
particularly important in this regard. Although multiple 
subtypes of nicotine receptor are expressed in the brain, 
attention has focused on a prevalent subtype (containing 
alpha 4 and beta 2 subunits) which is believed to represent 
the prime target for “smoking doses” of nicotine. The 
mesolimbic dopamine system, a neuronal population which 
5,691,365 
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has been implicated in the reinforcing actions of certain 
drugs (e.g. amphetamine), also appears to mediate the rein 
forcing actions of nicotine in laboratory rats. Pharmaco 
therapeutic approaches to smoking cessation rely on nicotine 
replacement. This publication argues that the administration 
of a selective antagonist of central nervous system nicotine 
receptors may lead to higher long-term abstinence rates, and 
research strategies for the development of such a drug are 
outlined 
The Journal of Substance Abuse, Vol. 1, No. 3, pp. 
259-71, 1989, describes dealing with the molecular features 
of nicotine, the receptor binding and psychotropic properties 
of nicotine agonists and antagonists, and the neuroanatomi 
cal locus of action of nicotine associated with its psycho 
tropic action. Bridged analogues of nicotine have been 
developed to de?ne the optimal conformation of the mol 
ecule for maximal receptor a?inity and psychotropic action 
in rats. With another series of analogues, it was demon 
strated that contraction of the pyrrolidine ring to a 4-member 
azetidine enhances potency while expansion diminishes it. A 
major site for nicotine’s central action is the vestibular 
cerebellum as demonstrated by kainic acid lesioning studies 
and direct administration of nicotine into this region. 
Included among the antagonists to nicotine was alpha 
lobeline, which appeared to be a mixed agonist-antagonist. 
Neuroendocrinology, Vol. 47, No. 4, pp. 303-8, April 
1988, discloses the e?tect of cholinergic agonists and antago 
nists on rat hypothalamic and corticotropin-releasing hor 
mone secretion in vitro. Acetylcholine (ACh) stimulated 
hypothalamic IR-rCRH secretion in a dose-dependent 
fashion, at concentrations ranging from 3.3X10(—10) to 
10(—5)M. This elfect was antagonized by the simultaneous 
presence of atropine and hexamethonium, a muscarinic and 
a nicotinic receptor antagonist, respectively (p less than 
0.05). Further evidence for the cholinergic regulation of the 
CRH neuron was provided by the ?ndings that both 
carbachol, a muscarinic receptor agonist, and nicotine, a 
nicotinic receptor agonist, stimulated IR-rCRH secretion in 
a dose-dependent fashion. These eifects were antagonized 
by atropine and hexamethonium, respectively, suggesting 
that both muscarinic and nicotinic receptors are involved in 
the process. 
The nicotine analogs of the present invention have not 
been disclosed by any prior art and unexpectedly have 
di?’erent properties than known compounds. The present 
nicotine analogs that have nicotinic receptor antagonist 
properties. The analog compounds are shown to competi 
tively inhibit dopamine release induced by nicotine. The 
nicotine analog compounds overcome the de?ciencies of 
prior art compounds and are useful in the treatment of 
nicotine abuse, smoking cessation therapy, as an antidote for 
nicotine intoxication, treatment of cognitive disorders such 
as Alzheimer’s disease and for the treatment of Parkinson’s 
disease. 
DISCLOSURE OF THE INVENTION 
The invention provides compounds of the following for 
mula: 
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4 
l 
I / CH3 
ti‘ 
CHg-R 
wherein R=N-alkyl or branched alkyl with 2-19 carbon 
atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19 
carbon atoms, and N -a1kynyl or branched alkynyl with 2-19 
carbon atoms. X=Cl", Br‘, 1“, H804“, 1AS042‘. These 
compounds are useful in the treatment of nicotine abuse, 
smoking cessation therapy, as an antidote for nicotine 
intoxication, treatment of cognitive disorders such as Alzhe 
imer’s disease and for the treatment of Parkinson’s disease. 
It is another object of the invention to provide compounds 
having nicotinic receptor antagonist properties. 
In a preferred embodiment the invention provides A 
method of antagonizing the nicotinic receptor comprising 
administering a pharmaceutically effective amount of a 
compounds of the invention. 
In still another embodiment the invention provides a 
method of treatment of nicotine abuse, as smoking cessation 
therapy, as an antidote for nicotine intoxication comprising 
administering a pharmaceutically e?’ective amount of a 
compound according to the invention. 
Advantageously the invention provides a method of treat 
ment of treatment of cognitive disorders selected from the 
group consisting of Alzheimer’s disease and Parkinson's 
disease comprising administering a pharmaceutically effec 
tive amount of a compound according to the invention. 
The above and other objects of the invention will become 
readily apparent to those of skill in the relevant art from the 
following detailed description and ?gures, wherein only the 
preferred embodiments of the invention are shown and 
described, simply by way of illustration of the best mode of 
carrying out the invention. As is readily recognized the 
invention is capable of modi?cations within the skill of the 
relevant art without departing from the spirit and scope of 
the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows structures of S(—)nicotine and related com 
pounds studied in [3H]DA release assays. Abbreviated 
nomenclature is given in parentheses. 
FIG. 2 shows IC50 values for N-substituted analogues of 
nicotine, nornicotine, and cotinine to inhibit nicotine-evoked 
[3H]DA release from rat striatal slices. 
FIG. 3 shows space ?lling models of minimum energy 
conformers of N'-protonated S(—)nicotine and the unproto 
nated and protonated forms of NONI. 
FIG. 4 shows overlay of the minimum energy conformers 
of protonated S(—)nicotine (red) and unprotonated S(—) 
NONI (black) showing the comparable N-N‘ intra-atomic 
distances in these molecules and the hypothetical mode of 
binding at the anionic site (A) and the hydrogen donor site 
(B) of the nicotinic receptor. 
DESCRIPTION OF THE INVENTION 
The present nicotine analogs have nicotinic receptor 
antagonist properties. The analog compounds are shown to 
competitively inhibit dopamine release induced by nicotine. 
The nicotine analog compounds overcome the de?ciencies 
of prior art compounds and are useful in the treatment of 
5,691,365 
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nicotine abuse, smoking cessation therapy, as an antidote for 
nicotine intoxication, treatment of cognitive disorders such 
as Alzheirner’s disease and for the treatment of Parkinson’s 
disease. . 
Hybridization cloning has revealed a surprising degree of 
subtype diversity among neuronal nicotinic receptors 
(Leutje et al. 1990a; Deneris et al. 1991); Role, 1992; 
Sargent, 1993). There are two types of neuronal nicotinic 
subunits 0t and [3. The on subunits are identi?ed by a pair of 
adjacent cysteine residues in the amino terminal domain and 
are traditionally thought of as the agonist-binding subunit. 
Eight subtypes of the ot subunit (0t2-0t9) and three subtypes 
of the {5 subunit (52-154) have been found in the vertebrate 
nervous system. The functional signi?cance of this subtype 
diversity is still a mystery. , 
Both native and cloned subtypes are pharrnacologically 
distinct in their response to both nicotinic agonists and 
antagonists. In terms of antagonists, ot-bungarotoxin 
(ot-BTX) selectively blocks receptors that contain the 0L7, 
0L8, or (19 subunits, and neuronal bungarotoxin (NBTX) 
selectively blocks the (1362 receptor (Leutje et al. 1990b). 
However, there are no selective toxins for receptors that 
contain the 0L2, 0L4, or [34 subunits. 
Nicotine activates presynaptic neuronal nicotinic recep 
tors evoking the release of dopamine (DA) from presynaptic 
terminals in the central nervous system (Giorguieif 
Chesselet et al. 1979; Westfall et al. 1993; Rowell et al. 
1987; Rapier et al. 1988, 1990; Grady et a1. 1992). The 
speci?c nicotinic receptor subtype which mediates nicotine 
evoked DA release has not been directly identi?ed, but has 
been suggested to be the (13132 subtype (Schulz et al. 1989; 
Grady et al. 1992). Developing subtype-selective antago 
nists are particularly important, because there are no selec 
tive toxins for receptors that contain the 0t2, 0t4, or [54 
subunits. Furthermore, development of subtype selective 
antagonists for the 01352 subtype is important, because 
NBTX is practically unavailable due to export restrictions 
on the source snakes. 
The invention relates to the development of novel nico 
tinic antagonists which inhibit nicotine-evoked dopamine 
release from rat striatal slices, with selectivity at the 013B2 
neuronal nicotinic receptor subtype. 
A series of N-substituted nicotine analogues were synthe 
sized and evaluated for their ability to inhibit nicotine 
evoked [3H]dopamine([3H]DA) release from rat striatal 
slices. Of the eleven compounds examined, the most e?i 
cacious analogues were those that contained a pyridino 
N-alkyl substituent of three carbons or more in length. 
Structure-activity relationships indicate that the order of 
potency correlated with increase in alkyl chain length. 
Introduction of an aromatic or unsaturated residue into the 
pyridino-N substituent also afforded compounds with sig 
ni?cant antagonist activity. The most e?icacious and potent 
compound in the series was S-N-octylnicotinium iodide 
(NONI). 
NONI had a potency approximately half that of the 
classical nicotinic antagonists, mecamylamine and dihydro 
[i-erythroidine (DHBE). Moreover, NONI completely 
blocked the effect of nicotine to evoke [3H]DA release, 
whereas the classical antagonists inhibited but did not com 
6 
pletely block nicotine‘s e?’ect. Furthermore, NONI did not 
possess agonist activity at concentrations which completely 
blocked nicotine-evoked [3H]DA release. The pKa values 
determined for S(—)nicotiue and one of the most active 
5 antagonists, S-N-allyl-nicotinium iodide (NANI), shows 
that these analogues exist predominantly in their unproto 
nated form at physiological pH. 
Molecular modeling studies suggest that these antagonists 
may interact with the nicotinic receptor in a novel binding 
mode which is diiferent from the mode of interaction of 
nicotine with this receptor. This structure-activity data pro 
vides useful information on the antagonist pharmacophore 
of the nicotine receptor subtype responsible for modulation 
of dopamine release from presynaptic terminals in the brain. 
Thus, it is proposed that these antagonists bind to the 
10 
receptor in their nnprotonated forms and that the binding‘ 
mode involves interaction of the quaternary pyridinium-N 
atom with the anionic site of the receptor. The unprotonated 
pyrrolidine-N atom serves as the hydrogen bond acceptor, 
which reverses the roles the nitrogens normally play in the 
binding of nicotine to the receptor. The N-alkyl substituent 
most likely binds to a site that extends beyond the normal 
agonist pharrnacophore volume which may prevent the 
receptor protein from achieving its open-channel quaternary 
form. 
Thus, a new class of e?icacious nicotinic antagonists have 
been discovered which inhibit nicotine evoked [3H]DA 
release from dopaminergic nerve terminals in the brain 
providing new tools for unraveling the role of neuronal 
nicotinic receptors modulating dopamine release. A descrip 
tion of synthesis methods for these compounds, their phar 
maceutical formulations and their methods of use are set 
forth below. 
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Synthesis. Several N-substituted analogues of S(—) 
nicotine (I), S(—)cotinine (I1) and racernic nornicotine (III) 
were prepared (FIG. 1 and Table 1) and evaluated for their 
ability to act as antagonists at neuronal nicotinic receptors 
(Tables 2 and 3). Compounds IVA-G were synthesized via 
direct alkylation of the pyridine-N atom of S(—)nicotine 
following a modi?cation of the method reported by Shiba 
gaki et a1. (1982). Compound V was synthesized by the 
method of McKennis et al. (1963), and compound VII was 
synthesized using a modi?cation of the method employed by 
Seeman and Whidby (1976). Compound VIA was prepared 
from racemic nornicotine via the reported method of Pool 
(1987). Compound VIB was prepared by reaction of racemic 
nornicotine with allyl iodide (Table I). All products were 
characterized by elemental analysis which afforded values 
that did not deviate by 10.40% of theoretical values, and by 
1H-NMR. The 1H-NMR spectra of compounds IVA-G were 
consistent with alkylation occurring at the pyridine-N atom 
rather than at the pyrrolidine-N atom, as indicated by the 
down?eld chemical shift values for the aromatic protons 
compared to the values for the same protons of nicotine. The 
pyrrolidine N-methyl group exhibited a similar chemical 
shift (approximately 2.3 ppm) for the NCH3 singlet in both 
nicotine and nicotine analogues IVA-G. Synthetic and ana 
lytical data for the above compounds is provided in Table 1. 
45 
55 
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TABLE 1 
Surihetic and anal?ical data for N-substituted nicotine analoggs 
Reaction Reaction Reaction % Melting 
Compound’ R X Solvent Temperature Tune Puri?cationb Yield Point (°C.) 
S-IVa NMNI H I- AcOH re?ux 12 h A 75 165-166 
S-IVb NPNI CH2CH3 I- AcOH . ambient 48 h B 56 83-84 
S-IVC NAN] CH=CH2 I- AcOl-l ambient 48 h B 64 88-90 
S-IVd NnBNI (C]-l¢)2CI-[3 I- MeOH +55° C. 48 h ehromatogr. 40 81-82 
s- Ve NONI (crrzkcrr, r- MeOH +ss° c. 48 h B 20 oil 
S-IVf NBNB C611, Br- AcOH +55° C. 24 h B 65 159-160 
S-IVg NHEN'I CH2OH I- MeOl-I +55° C. 48 h chromatogr. 55 hygroscopic 
S-V N'MCI — I- MeOH +50‘7 C. 3 h C 79 147-148 
(:t:)VIa NT-IIN'NI Rl=CH3;R2=H I- AcOH ambient 24 h D 67 207-209 
(i)Vl'b DNANI Rl=R2dCH2CH=CH3 I- THF ambient 24 h B 55 123-124 
S-VH PIPNNN — I- MeOH ambient 24 h D 60 135-137 
‘See Figure 1 for structures of compounds. 
"Metlnd of Puri?cation: A, After evaporation of the solvents and addition of sat'ln'ated Nail-[C03, the basic solution (pl-I = 8) was 
washed with other before extraction with chloroform. B, Column chromatography over silica gel elution with 5% MeOH in 
chloroform. C, Recrystalization from MeOH. D, Preparative cation-exchange H'PDC. 
pKa Determination. A solution [1 g in 12 rnls of deuterium 
oxide 100% atom D] of the compound under investigation 
was gradually acidi?ed by drop-wise addition of a solution 
of DC1 to D20 (20% wt/wt, 99.5% atom D). The pD values 
were measured on a Corning pH meter. For each pD value, 
a sample (0.8 rnls) was analyzed by 1H-NMR on a Varian 
Unity 300 MHz spectrometer using sodium 3(nimethy1silyl) 
-2,2,33-d4-propionate (TSP) as internal reference. Protona 
tion of the pyrrolidine- and pyridine-N atoms was followed 
by observing the variation in chemical shift of the N-1' 
methyl and 2‘-proton signals from p0 8.8 to pD 3.0. A 
titration curve of pD vs chemical shift was constructed to 
determine the pKa values of pyrrolidino-N atom and/or the 
pyridine-N atom. 
Computational Chemistry. A solution [1 g in 12 rnls of 
deuterium oxide 100% atom D] of the compound under 
investigation was gradually acidi?ed by drop-wise addition 
of a solution of DC1 to D20 (20% wt/wt, 99.5% atom D). 
'Ihe pD values were measured on a Corning pH meter. For 
each pD value, a sample (0.8 rnls) was analyzed by 1H-NMR 
on a Varian Unity 300 MHZ spectrometer using sodium 
3-(trimethylsilyl)-2,2,33-d4-propionate (TSP) as internal 
reference. Protonation of the pyrrolidine- and pyridine-N 
atoms was followed by observing the variation in chemical 
shift of the N-l'methyl and 2‘-proton signals from pD 8.8 to 
pD 3.0. A titration curve of pD vs chemical shift was 
constructed to determine the pKa values of pyrrolidino-N 
atom and/or the pyridine-N atom. 
Computational Chemistry. The molecular modeling pack 
age HYPERCHEM© (AutodesK, Inc. California) was used 
to calculate energy-minimized conformers of protonated and 
unprotonated molecules. Partial charges were calculated 
using External Hiickel Methods, and structures were ruini 
rnized with the MM+ molecular mechanics force ?eld, using 
Polak-Ribiere as the minimization algorithm, 
Biological Methods. Male Spragua-Dawley rats (150-200 
g) were obtained from Harlan Laboratories (Indianapolis, 
Ind.) and were housed two per cage with free access to food 
and water in the Division of Lab Animal Resources at the 
College of Pharmacy at the University of Kentucky. Experi 
mental protocols involving the animals were approved by 
the Institutional Animal Care and Use Committee at the 
University of Kentucky. 
[3H]DA Release Assay. Rat striatal slices (500 um 
thickness, 6-8 mg wet weight) were obtained as previously 
described (Dwoskin and Zahniser, 1986). Slices were incu 
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bated for 30 min in Krebs’ buifer (in nM; 118 NaCl, 4.7 KCl, 
1.2 MgCl2, 1.0 NaH2P04, 1.3 CaCIQ, 1.3 CaClz, 11.1 
glucose, 25 NaHCO3, 0.11 L-ascorbic acid nd 0.004 diso 
dium EDTA; pH 7.4 and saturated with 95% O2/5% CO2) in 
a metabolic shaker at 34°. Slices were rinsed with 15 ml of 
fresh buffer and incubated for an additional 30 min in fresh 
buffer containing 0.1 pM [3H]dopa.mine (6 slices/3 ml). 
Subsequently, slices were rinsed with 15 ml of fresh bu?’er 
and transferred to a glass superfusion chamber. Slices were 
superfused (1.0 ml/min) for 60 min with Krebs’ buifer 
containing nomifensine (10 pm) and pargyline (10 pm) and 
maintained at 34° C., pH 7.4 with continual aeration (95% 
O2/5% C0,). rIwo 5-min samples (5 ml) were collected to 
determine basal out?ow of [3H]DA. N-Substituted nicotine 
analogues were added to the superfusion bu?’er after the 
collection of the second sample and remained in the butfer 
until 12 consecutive S-min samples were collected. 
Subsequently, S(—)nicotine (10 M) was added to the buffer 
and an additional 12 consecutive 5-min samples were col 
lected. At the end of the experiment each slice was solubi 
lized and the [3H] content of the tissue determined. 
Radioactivity in the superfusate and tissue samples was 
determined by liquid scintillation spectroscopy. Fractional 
release for each superfusate sample was calculated by divid 
ing the total tritium collected in each sample by the total 
tritium present in the tissue at the time of sample collection. 
Basal [3H]out ?ow was calculated from the average of the 
tritium collected in the two 5-min samples just before 
addition of the N-substituted nicotine analogue. The sums of 
the increase in collected tritium resulting from either expo 
sure to the test compound or exposure to nicotine in the 
absence and presence of the test compound equaled total 
[3H]over?ow. [3H]over?ow was calculated by subtracting 
the [3H] out?ow during an equivalent period of prestimula 
tion from the values in samples collected during and after 
drug exposure. Inasmuch as the radiolabelled compounds 
were not separated and identi?ed, the tritium collected in 
superfusate is referred to as either [3H]out?0w or [3H] 
over?ow, rather than as [3H]DA. [3H]Over?ow primarily 
represents [3H]DA in the presence of nornifensine and 
pargyline in the superfusion buffer (Zumstein et a1. 1981). 
The effects of the nicotinic agonist, S(—)nicotine, and two 
of its metabolites, S(—)cotinine and (i)nornicotine, on [3H] 
DA release from rat striatal slices are shown in Table 2. 
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TABLE 2 
TABLE 2. The e?ect of S(—)nicotine, S(—)cotinine, S(—)cytisine 
and racernic nomicotine on 135 EA release from rat striatal slices 
Concentration 1M] 
Compound N‘ 1 10 100 
S(—)nicotine 9 2.80 i 0.28" 3.24 i 0.37 5.56 i 0.50 
S(—)cystisine 5 0.67 i 0.26 0.85 i 0.38 1.13 i 0.46 
S(—)ootinine 6 0 i: 0 1.14 i 0.36 2.06 :l: 0.35 
(i)norniootine 8 1.40 :t 0.24 2.60 i 0.38 4.20 i 0.34 
‘N = number of animals. 
"Data are expressed as total [al-?over?ow, mean i SEM. 
The effect of the high a?inity nicotinic ligand, S(—) 
cytisine, was also evaluated for its ability to release [3H]DA 
from striatal slices. From these data, S(—)nicotine produced 
a concentration-dependent increase in [3H]DA release and 
was the most potent and e?icacions compound compared to 
the other agonists studied. Racemic nornicotine also pro 
duced a concentration-dependent increase in [3H]DA 
release, but evoked release which was only 50% of the effect 
produced by S(—)nicotine at 1 M, and approximately 80% 
of that at the higher concentrations. The effect of racemic 
nornicotine was compared with that of S(—)nicotine because 
of the reported lack of stereoselective e?ect of nornicotine 
(Reavill et a1. 1988; Copeland et a1. 1991; Risner et al. 1985, 
1988; Goldberg et al. 1989) and due to the di?iculty in 
obtaining enatiomerically pure forms of nornicotine. 
Cotinine, the major metabolite of nicotine, had no effect at 
1 pM, and only produced a small effect (35% of nicotine’s 
e?ect) at the higher concentrations. 
The N-substituted nicotine analogues described in Table 1 
were evaluated for their ability to evoke [3H] release from 
rat striatal slices at three concentrations (1, 10 and 100 pM) 
(Table 3). 
TABLE 3 
The elfect of DHBE, MEC and N-substit'uted nicotine 
analo s on DA release from rat striatal slices 
Concentration 1 M] 
Com 
potmd N‘ 0 1 10 100 
NONI 6 0.01 :t: 0.011’ 0.03 :1: 0.02 0.14 i 0.14 16.4 :1: 2.00 
DHBE 5 0.00 :t 0.00 0.02 :t: 0.02 0.36 i 0.22 2.01 :k 0.28 
NBC 4 0.00 i 0.00 0.00 i 0.00 0.00 :i: 0.00 0.00 i 0.00 
NBNB 7 0.05 i 0.05 0.21 i 0.12 0.28 i 0.12 6.04 i 0.97 
NPNI 8 0.00 :1: 0.00 0.06 i 0.01 0.03 i 0.03 0.03 i 0.03 
NnBNI 5 0.00 i 0.00 0.00 i 0.00 0.01 i 0.01 0.01 i 0.01 
NANI 9 0.00 :l: 0.00 0.02 i 0.02 0.07 i 0.04 0.08 i 0.03 
NHENI 6 0.10 i 0.07 0.00 i 011) 0.00 :1: 0.00 0.08 i 0.04 
(It) 5 0.02 i 0.01 0.02 i 0.01 0.08 i 0.04 0.00 :t 0.00 
DNANI 
(i) 5 0.00 i: 0.00 0.17 i 0.11 0.01 i 0.01 2.60 i 0.38 
N'MNNI 
NW1 5 0.02 i 0.01 0.13 i: 0.11 0.17 i 0.10 0.08 i 0.06 
NMCI 5 0.00 :t 0.00 0.00 i 0.00 0.01 i: 0.01 0.02 :i: 0.01 
PIPN'MN 4 0.00 d: 0.00 0.03 i 0.03 0.01 i 0.01 0.05 i 0.02 
N‘ = number of animals. 
t’Dat:a are expressed as total [311] over?ow, mean i S.E.M. 
In addition, the classical competitive and noncompetitive 
nicotinic antagonists, DHBE (Vidal and Changeux, 1989; 
Alkondon and Albuquerque 1991; Mulle et a1. 1991) and 
mecamylamine (Grenhoff and Svensson, 1989; Mulle et a1. 
1991) were also examined in this assay for the sake of 
comparison. None of the compounds examined, including 
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DI-[BE and rnecamylmine, had any signi?cant eifect on 
[3H]DA release in the concentration range of 1-10 11M. 
However, at the highest concentration (100 PM) examined, 
HONI, NBNB, and (i)NMNNI evoked [3H]DA release and 
thus, possess intrinsic agonist activity at this concentration. 
In particular NONI was quite e?icacious and exhibited 
three-times the agonist activity of nicotine at the 100 |.|M 
concentration. At this high concentration, DHBE also 
evoked [3H]DA release (Table 3). 
The N-substitnted nicotine analogues were evaluated for 
their ability to inhibit nicotine-evoked [3H]DA release 
(Table 4). 
TABLE 4 
N-Substituted nicotine analogue-induced antagonism of 
S(—)nicotine (l0 pM)-evoked [3H]DA release from rat 
striatal slices 
__.—®11s=_m_ti°atM)__— 
Com 
pound N‘ 0c 1 10 100 
NONI 6 1.84 i 0.201: 1.21 :t 0.14 0.03 :t 0.02 NDd 
DHBE 5 3.10 i 0.60 1.59 i 0.09 0.73 i 0.12 ND 
NBC 4 2.64 i 0.84 0.87 :1: 0.18 0.68 t 0.23 0.41 :l: 0.31 
N'BNB 7 2.98 i 0.51 1.50 :t: 0.55 1.27 i 0.35 ND 
NPNI 8 2.06 i 0.45 1.63 :t 0.41 0.88 :l: 0.51 0.31 :i: 0.13 
NnBNI 5 2.3 i 0.41 2.70 i 0.52 1.03 i: 0.28 0.39 i 0.09 
NANI 9 1.96 i 0.29 2.61 i 0.46 0.92 i 0.35 0.48 i 0.18 
NHEN'I 6 2.45 :l: 0.40 1.66 i 0.10 2.13 i 0.38 0.34 i 0.11 
(i) 5 1.94 i 0.39 2.58 i 0.54 1.85 i 0.25 1.66 :1: 0.36 
DNANI 
(i) 5 2.97 i: 0.48 2.22 i 1.26 3.53 i 0.85 ND 
NMNNI 
NMNI 5 1.94 i 0.29 2.10 i 0.81 3.33 i 1.27 1.65 i 0.90 
NMCI 5 2.97 i 0.48 3.11 i: 1.32 3.11 i 1.20 3.75 i 1.66 
PIPNMN 4 3.07 :i: 0.61 3.16 i 1.46 2.98 i 1.48 1.88 :t 0.77 
N“ = number of animals. 
'’Data are expressed as total [3H]over?ow, mean i S.E.M. during 
co-superfusion with 10 1.1M nicotine. 
°Nicotine (10 uM)-evoked total [al?over?ow determined for each experi 
ment. Grand mean was 2.52 :t 0.12 with a range of 1.03-4.65 for N = 82 
awnpiim as a result of intrinsic agonist activity. 
In these experiments, the striatal slices were superfused for 
60 min with various concentrations of the analogues prior to 
nicotine (10 pM) exposure. Antagonist activity was evalu 
ated by comparing the nicotine-evoked [3H] over?ow in the 
absence and presence of the analogues. From the group of 
quaternary ammonium analogues examined, PIPNMN, 
NMCI, NMNI, (i)NMNNI, and (i)DNANI did not exhibit 
signi?cant nicotinic antagonist activity over the concentra 
tion range tested. However, it should be noted that two of 
these inactive compounds are racemates. Signi?cant antago 
nist activity was observed with NHENI, NANI, NnBNI, 
NPNI, NBNB and NONI. The relative order of potency of 
the classical and pyridine-N substituted nicotine analogues 
for inhibition of nicotine-evoked [3H]DA release from rat 
striatal slices is illustrated in FIG. 2 by a comparison of their 
IC50 values. The order of potency wherein NONI>>DIIBE= 
MEC>>NBNB=NPNI=NnNBI=NANI>NHENI>>>(i)di 
N-allyl nicotiniurn iodide (DNANI)=(i)N-methyl nornico 
tinium iodide (NMNN'I)=NMNI=S-N-methyl cotininium 
iodide (NMCI)=S-N‘-methyl nicotinium iodide (PIPNMN). 
The most potent and e?icacious antagonist in this series of 
analogues was clearly NONI (Table 4 and FIG. 2). At the 
low concentration of 10 PM, NONI completely inhibited 
nicotine-evoked [3H]DA release. Furthermore, NONI was 
16-fold more elfective than DHBE and MEC at this con 
centration. However, the NONI-induced inhibition of the 
etfect of nicotine could not be determined at the 100 pM, 
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since similar to DHBE, NONI possessed intrinsic agonist 
activity at this high concentration. It is important to note, 
however, that the intrinsic agonist activity of NONI was 
observed at a concentration 10-fold higher than that required 
to completely inhibit nicotine-evoked [3H]DA release. 
Determination of the pKa value of the pyrrolidino-N 
functionality of NANI by H-NMR analysis a?orded a value 
of 6.4 This value for NANI was considerably lower than the 
pKa value of 8.4 for the same functionality in the nicotine 
molecule when analyzed in ‘an identical manner. The 
pyridine-N functionality of nicotine afforded a pKa value of 
3.75. These results indicate that at physiological pH (7.6) the 
quaternary nicotine analogues exist predominantly in their 
unprotonated forms whereas, nicotine exists predominantly 
in its N- 1‘ protonated form. Thus, both molecules are mono 
cationic at physiological pH, but the positive charge in the 
respective molecules is located on diiferent nitrogen atoms. 
Conformational analysis data for nicotine and the three 
most effective antagonists provides information on the 
energy-minimized conformations of the protonated and 
unprotonated forms of these compounds (‘Table 5). 
TABLE 5 
Table 5. Characteristics of ‘ ations for ' energyconform 
' - sofnicotine ammonium analo 
C(3)-4J(2') 
N—N' Inna-atomic Distance Torsion Angle 
comwmd (Ansstmm) (Dames) 
Nicotine 
free base 4.35 109.8 
nnmprotonated (N""H) 4.19 113.2 
diprotonated 4.70 117.0 
NBNB 
monocation 4.04 112.2 
dicntion (N"‘H) 4.90 115.7 
NANI 
nnmcation 4.00 111.4 
dication (Nl‘H) 4.81 117.7 
NONI 
monocation 4.08 111.2 
dicntion (1W1!) 4.70 116.8 
As expected, generation of a dicationic species of these 
compounds results in a signi?cant change in the N-N‘ 
intra-atomic distance as compared to the monocationic spe 
cies. This is due to the charge repulsion between the two 
positive nitrogen centers, which induces a signi?cant rota 
tion about the C(3)-C(2') bond. Since the NMR data indi 
cates that it is predominantly the monocationic form of the 
antagonist that exists at physiological pH, it is likely that this 
is the form that interacts with the nicotinic receptor. It is 
interesting to note that the N-N' intra-atomic distance and 
the C(3)-C(2') torsion angle value for the monocationic (i.e., 
unprotonated) forms of the antagonist molecules‘ corre 
sponds quite closely to the same values for the monoproto 
nated S(—)nicotine species. 
As has been previously reported (Giorguie?-Chesselet et 
al. 1979; Westfall et al. 1983; Rowell et al. 1987; Rapier et 
al. 1988, 1990; Grady et al. 1992; Dwoslcin et al. 1993), 
nicotine and nornicotine evoked a concentration-dependent 
increase in [3H]D'A release from rat striatal slices; however, 
nornicotine was less potent in producing this effect. In the 
current study, the ECSO value for nicotine was=2 M, which 
is within the wide range of ECSO values (10 nM-lO pM) 
reported by others (vide supra) using various preparations 
and nicotine exposure times. 
10 
25 
30 
35 
45 
50 
55 
65 
12 
S(—)Cotinine, the major metabolite of S(—)nicotine 
detected in brain (Petersen et al. 1984); Stalhandske, 1970) 
had little etfect even at high concentrations in the DA release 
assay. Interestingly, the high ai?nity ligand S(—)cytisine only 
marginally released dopamine from the stn'atal slice, pro 
ducing approximately 20% of the etfect of nicotine at each 
concentration examined in the present study. These results 
are in agreement with others (El-Bizri and Clarke, 1994) 
reporting a lesser e?’ect of cytisine compared to nicotine in 
evoking dopamine release from rat striatal synaptosomes. 
The results suggest that the nicotinic receptor subtype modu 
lating DA release may be dilferent from nicotinic receptor 
subtype(s) that avidly bind [3H]nicotine and [3H]cytisine. 
Unexpectedly, DHBE, the competitive nicotinic 
antagonist, evoked [3H]DA release at the highest concen 
tration examined (Table 3). This etfect has not been previ 
ously reported. It is doubtful whether concentrations of 
DHBE as high as 100 PM have physiological relevance in 
vivo. Nevertheless, this concentration of DHBE is used 
routinely for nicotinic receptor antagonism in in vitro phar 
macological studies (Grady et al. 1992; El-Bizri and Clarke, 
1994). 
From structure-activity considerations of the series of 
nicotine analogues examined, it is evident that quaterniza 
tion of the pyridine-N atom of S(—)nicotine can result in 
compounds that possess antagonist activity in the nicotine 
evoked [3H]DA release assay. Greatest antagonist potency 
was obtained with an pyridine-N substituent (NONI) bearing 
eight carbons in a linear chain. Smaller carbon chains (two 
to ?ve) had signi?cantly lower potency and e?icacy (i.e., 
NANI, NPNI, NnBNI, and NBNB). Consistent with this 
trend in structure activity is the ?nding that introduction of 
a sterically small pyridine-N substituent atfords an analogue, 
NMNI which exhibits no antagonistic activity. Similarly, 
pyridino-N-methylation of both S(—)continine and 
(i)nornicotine also aiforded compounds (NMCI and NMNI, 
respectively) which were devoid of antagonist activity. 
Pyridine-N quaternization of a nicotine analogue in which 
the pyrrolidine-N-methyl group has been substituted by a 
larger alkyl group (i.e., N-allyl, see (i)DNANI) results in 
relatively weak antagonist activity compared to the N-allyl 
nicotine analogue (NANI). 
Introduction of unsaturated or aromatic moieties into the 
pyridine-N substituent structure also results in compounds 
possessing antagonist activity (e.g., NANI nd_ NBNB, 
respectively). Thus, a relatively-long, linear, alkyl chain 
representing a substituent that is lipophilic in nature appears 
to be an important determinant of antagonist activity in these 
quaternary ammonium analogues of nicotine. Antagonists 
are almost always large molecules, which, if docked onto the 
agonist, would extend outside the normal against volume. 
Thus, the extra bulk associated with the antagonist structures 
may prevent the receptor protein from achieving the open 
channel quaternary form. 
The inventors show the molecules described are binding 
to the antagonist site in their unprotonated forms and that the 
binding mode involves interaction of the quaternary ammo 
nium nitrogen with the anionic site of the receptor. The 
unprotonated tertiary amine (i.e. the pyrrolidine N) interacts 
with the hydrogen-bond donor site. This is the reverse of the 
normal binding mode of an agonist such as nicotine (FIG. 3). 
‘The pKa values for the quaternary nicotine analogues is in 
accord with this hypothesized mode of binding, since it 
' clearly indicates that the most predominant species of the 
quaternary ammonium nicotine analogue at physiological 
pH is the unprotonated form; whereas in the case of S(—) 
nicotine, the most predominant form at this pH would be the 
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pyrrolidine-N protonated form. The locus of positive charge 
is thus switched from one nitrogen to the other in these two 
structures. 
The molecular modeling data on the three most active 
antagonists NANI, NONI and NBNB, provide the two 
pH-dependent, energy-minimized conformations in aqueous 
solution. The unprotonated species of NONI, the most active 
antagonist, in which the N-N‘ atomic distance is about 4.0 A 
is illustrated in FIG. 3. The N'-protonated species of this 
compound (FIG. 3) has an N-N' atomic distance which is 
signi?cantly greater than 4.0 A in its preferred conformation. 
This increase in intra-atomic N distance, which is most 
likely a result of ion repulsion between the two cationic 
centers, is equivalent to arotation of approximately 8° about 
the C(3)-C(2') bond of the monocationic molecule. 
The pKa for the n'-amino function of nicotine is 8.4, 
calculated from after 1H-NMR. Therefore, a physiological 
pH, nicotine exists predominantly (>95%) in the monoca 
tionic n'-protonated species. However, in the case of the 
three quaternary ammonium compounds described in Table 
5, the pKa of the N'-amino group is two units lower than in 
nicotine. This reduction in basicity of the pyrrolidino-N in 
the antagonist molecules is due to the existing positive 
charge on the molecule and also due to the B-electron 
withdrawing effect of the pyridinium moiety on the pyrro 
lidino N-atom. These two factors would make it more 
di?icult to protonate the N'-amino group. Thus, at physi 
ological pH, the antagonist molecules will exist predomi 
nantly in their unprotonated forms. 
The nicotinic receptor pharmacophore incorporates a cat 
ionic center (i.e., a protonated pyrrolidine-N of S(—) 
nicotine) and an electronegative atom that is able to partici 
pate in a hydrogen-bond interaction with a receptor moiety 
(i.e., the pyridino-N of S(—)nicotine. From the present data, 
an antagonist binding mode for the quaternary ammonium 
nicotine analogues is suggested. The pyridinium-N atom in 
the antagonist molecules occupies the anionic site of the 
nicotine receptor that normally accommodates the proto 
nated pyrrolidino-N functionality of the agonist S(—) 
nicotine. The unprotonated pyrrolidino-N atom of the 
antagonist then functions as the hydrogen-bond acceptor 
moiety. Thus, compared to the two nitrogen atoms in the 
nicotine molecule, the two nitrogen atoms in the antagonist 
molecules have interchanged their roles when binding to the 
nicotinic receptor, with a resulting change in activity from 
agonist to antagonist (FIG. 4). The size of the pyridino-N 
substituent is also an important factor governing antagonist 
e?icacy. This appears to indicate the presence of an addi 
tional lipophilic binding site or pocket constituting another 
important component of the antagonist pharmacophore. This 
binding site extends beyond the normal agonist pharma 
cophore volume. Thus, interaction of the antagonist with this 
site may prevent the receptor protein from achieving the 
open channel quaternary form. 
In sum, this work has resulted in the emergence of a new 
class of e?icacious nicotinic antagonist which inhibit nico 
tine evoked [1H]DA release from dopaminergic nerve ter 
minals. These antagonists appear to interact with the nico 
tinic receptor modulating dopamine release in a novel 
binding mode and may serve as new tools for unraveling the 
complexities of neuronal nicotinic receptors. 
For the purpose of this invention, the racemic mixtures 
and the dextro and levo forms are included within the 
present invention. The racemic mixtures and the dextro 
forms are preferred. 
Further, the compounds of the present invention are useful 
in pharmaceutical compositions for systemic administration 
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to humans and animals in unit dosage forms, such as tablets, 
capsules, pills, powders, granules, suppositories, sterile 
parenteral solutions or suspensions, sterile non-parenteral 
solutions or suspensions oral solutions or suspensions, oil in 
water or water in oil emulsions and the like, containing 
suitable quantities of an active ingredient 
Topical application can be in the form of ointments, 
creams, lotions, jellies, sprays, and the like. For oral admin 
istration either solid or ?uid unit dosage forms can be 
prepared with the compounds of the invention. The com 
pounds are useful in pharmaceutical compositions (wt %) of 
the active ingredient with a carrier or vehicle in the com 
position in about 1 to 20% and preferably about 5 to 15%. 
Either ?uid or solid unit dosage forms can be readily 
prepared for oral administration. For example, the com 
pounds of the invention can be mixed with conventional 
ingredients such as dicalciumphosphate, magnesium alumi 
num silicate, magnesium stearate, calcium sulfate, starch, 
talc, lactose, acacia, methyl cellulose and functionally simi 
lar materials as pharmaceutical excipients or carriers. A 
sustained release formulation may optionally be used. Cap 
sules may be formulated by mixing the compound with a 
pharmaceutical diluent which is inert and inserting this 
mixture into a hard gelatin capsule having the appropriate 
size. If soft capsules are desired a slurry of the compound 
with an acceptable vegetable, light petroleum, or other inert 
oil can be encapsulated by machine into a gelatin capsule. 
Suspensions, syrups and elixirs may be used for oral 
administration of ?uid unit dosage forms. A ?uid preparation 
including oil may be used for oil soluble forms. A vegetable 
oil such as corn oil, peanut oil or safflower oil, for example, 
together with ?avoring agents, sweeteners and any preser 
vatives produces an acceptable ?uid preparation. A surfac 
tant may be added to water to form a syrup for ?uid unit 
dosages. Hydro-alcoholic pharmaceutical preparations may 
be used having an acceptable sweetener such as sugar, 
saccharine or a biological sweetener and a ?avoring agent in 
the form of an elixir. 
Pharmaceutical compositions for parenteral and supposi 
tory administration can also be obtained using techniques 
standard in the art. The above parenteral solutions or sus 
pensions may be administered transdermally and, if desired 
a more concentrated slow release form may be administered. 
Accordingly, incorporation of the active compounds in a 
slow release matrix may be implemented for administering 
transdermally. The compounds may be administered trans 
dermally at about 1 to 20% of the composition and prefer 
ably about 5 to 15% wt % of the active ingredient in the 
vehicle or carrier. 
Transdermal therapeutic systems are self-contained dos 
age forms that, when applied to intact skin, deliver drug(s) 
at a controlled rate to the systemic circulation. Advantages 
of using the transdermal routing include: enhanced thera 
peutic e?icacy, reduction in the frequency of dosing, reduc 
tion of side e?’ects due to optimization of the blood 
concentration versus time pro?le, increased patient 
compliance due to elimination of multiple dosing schedules, 
bypassing the hepatic “?rst-pass” metabolism, avoiding 
gastrointestinal incompatibilities and providing a predict 
able and extended duration of activity. However, the main 
function of the skin is to act as a barrier to entering 
compounds. As a consequence, transdermal therapy has so 
far been restricted to a limited number of drugs that possess 
the desirable physiochemical properties for diffusion across 
the skin barrier. One e?ective method of overcoming the 
barrier function of the skin is to include a penetration 
enhancer in the formulation of a transdermal therapeutic 
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system. See Barry, Brian W.: Dermatological Formulations: 
Percutaneous Absorption (Dekker, New York, 1983); 
Bronough et al, Percutaneous Absorption, Mechanisms 
Methodology-Drug Delivery, (Marcel Dekker, New York, 
NY. 1985); and Monkhouse et al, Transdennal drug deliver 
problems and promises. Drug Dev. Ind. Pharm., 14, 
183-209 (1988). 
A penetration enhancer is a chemical compound that, 
when included in a formulation, temporarily increases the 
permeability of the skin to a drug allowing more of the drug 
to be absorbed in a shorter period of time. Several different 
types of penetration enhancers have been reported such as 
dimethylsulfoxide, n-decyl methyl sulfoxide, N,N 
dimethylacetamide, N<Ni-dimethylformamide, 
l-dodecylazacycloheptan-Z-one (Azone), propylene glycol, 
ethanol, pyrrolidones such as N-methyl-2-pyrrolidone 
(NMP) and surfactants. See Bronough et a1, supra, and 
Stoughton et al, Azone: a New Non-toxic enhancer of 
percutaneous penetration. Drug Dev. Inc. Pharm., 9, 
725-744 (1983). 
N-methyl-Z-pyrrolidone is a versatile solvent which is 
miscible with water, ethyl alcohol, ether, chloroform, 
benzene, ethyl acetate and carbon disul?de. 
N-methylpyrrolidone has been widely used as a solvent in 
industrial processes such as petroleum re?ning, GAF Corp.: 
“M-Pyrol (N-methyl-2-pyrrolidone) Handboo ”, GAF 
Corp., New York, 1972. It is currently used as a solubilizing 
agent in topical and parenteral veterinary pharmaceuticals 
and is now under consideration for use in products intended 
for humans, Wells, D. A. et a1: Disposition and Metabolism 
of Double-Labeled [3H and 1“C] N-methyl-2-pyrrolidone in 
the Rat. Drug Met. Disps., 16, 243-249 ( 1988). Animal and 
human experiments have shown very little irritation or 
sensitization potential. Ames type assays and chronic expo 
sure studies have not revealed any signi?cant toxicity, Wells 
et al, Mutagenicity and (brtotoxicity of N-methyl-2-p 
[yn'olidone and 4-(methyl amino) Butanoic Acid in the 
Salrnonella/microsome Assay. J. AppL T0x., 8, 135-139 
(1988). N-methylpyrrolidone has also been shown to be an 
e?ective penetration enhancer. Barry et al, Optimization and 
Bioavailability of Topical Steroids: Penetration Enhancers 
Under Occlusion. J. Inv. Derm., 82, 49-52 (1984); Akter et 
al, Absorption Through human Skin of Ibuprofen and Flur 
bip'ofen; Effect of Dose Variation, Deposited Drug Films, 
Occlusion and the Penetration Enhancer N-methyl-2 
pyrrolidone. J. Phamt. Phar-macol, 37, 27-37 (1984); Hole 
gaard et al, Vesical Eifect on Topical Drug Delivery IV. 
F?ect of N-methylpyrrolidone and Polar Lipids on Percu 
taneous Transport Int. J. Pharm, 43, 233-240 (1988); 
Sugibayashi et al, Effect of Several Penetration Enhancers 
on the Percutaneous Absorption of Indomethacin in Hairless 
Rat. Chem. Pharm. Bull, 36, 1519-1529 (1988); Bennett et 
al, Optimization of Bioavailability of Topical Steroids: Non 
occluded penetration Enhancers Under Thermodynamic 
Control. J. Pharm. PharmacoL, 37, 298-304 (1985); Sasaki 
et al, Enhancing Effect of Pyrrolidone Derivatives on Trans 
derman Drug Delivery. 1. lug. J. Phame, 44, 14-24 (1988); 
lee et al, Toxicity of N-methyl-2-pyrrolidone (NMP): 
Tetratogenic, Subchronic and Two-year Inhalation Studies, 
Fund. AppL, Tox., 9, 222-235 (1987). 
The above and other drugs can be present in the reservoir 
alone or in combination form with pharmaceutical carriers. 
The pharmaceutical carriers acceptable for the purpose of 
this invention are the art known carriers that do not 
adversely a?ect the drug, the host, or the material compris 
ing the drug delivery device. Suitable pharmaceutical car 
riers include sterile water; saline, dextrose; dextrose in water 
20 
25 
35 
45 
50 
55 
65 
16 
or saline; condensation products of castor oil and ethylene 
oxide combining about 30 to about 35 moles of ethylene 
oxide per mole of castor oil; liquid acid; lower alkanols; oils 
such as corn oil; peanut oil, sesame oil and the like, with 
emulsi?ers such as mono- or di-glyceride of a fatty acid, or 
a phosphatide, e.g., lecithin, and the like; glycols; polyalky 
lene glycols; aqueous media in the presence of a suspending 
agent, for example, sodium carboxymethylcellulose; sodium 
alginate; poly(vinylpyrol idone); and the like, alone, or with 
suitable dispensing agents such as lecithin; polyoxyethylene 
stearate; and the like. The carrier may also contain adjuvants 
such as preserving stabilizing, wetting, emulsifying agents 
and the like together with the penetration enhancer of this 
invention. 
The eifective dosage for mammals may vary due to such 
factors as age, weight activity level or condition of the 
subject being treated. Typically, an effective dosage of a 
compound according to the present invention is about 10 to 
400 mg when administered by either oral or rectal dose from 
1 to 3 times daily. Preferably about 20 to about 200 mg are 
administered orally or rectally 1 to 3 times a day for an adult 
human. The required dose is considerably less when admin 
istered parenterally, preferably about 10 to about 50 mg may 
be administered intrarnuscularly or transdermally, 1 or 2 
times a day for an adult human. 
In sum the invention provides a compound of the follow 
ing formula: 
‘E, ] Xe \ ‘0 If 
I / CH3 
at‘ 
CH1—R 
wherein R=N-a]kyl or branched alkyl with 2-19 carbon 
atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19 
carbon atoms, and N-alkynyl or branched alkynyl with 2-19 
carbon atoms; and X=C1_, Br“, 1“, H504‘, ‘AS0421 Com 
pounds in which R is branched alkyl with 2-19 carbon atoms 
or R is a cycloalkyl or aralkyl group are preferred. In 
addition compounds wherein in X is I“, are also preferred. 
More particularly compounds selected from the group 
consisting of S-N-hydroxyethyl nicotinium iodide 
(NHENI), S-N-nbutyl nicotinium iodine (NnBNI), S-N 
propyl nicotinium iodide (NPNI), S-N-benzyl nicotinium 
bromide (NBNB), S-N-octylnicotinium iodide (NONI), and 
S-N-allylnicotinium iodide (NANI) have been shown to 
have preferred nicotinic receptor antagonist activity. 
The compounds of the invention can be used in a method 
of antagonizing the nicotinic receptor comprising adminis 
tering a pharrnaceutically effective amount of the com 
pound. 
DETAILED DESCRIPTION OF_ THE DRAWINGS 
FIG. 1. Structures of S(-)nicotine and related compounds 
studied in [3H]DA release assays. Abbreviated nomenclature 
is given in parentheses. 
FIG. 2. IC50 values for N-substituted analogues of 
nicotine, nornicotine, and cotinine to inhibit nicotine-evoked 
[3H]DA release from rat striatal slices. Inhibition produced 
by the classical nicotinic inhibitors, mecarnylamine (MEC) 
and DHBE was also detennined. Slices were superfused 
with inhibitor for 60 min following co-superfusion with 10 
M nicotine. Inhibition was determined by comparing [3H] 
DA release in the absence and presence of various concen 
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trations of inhibitor. IC50 values were determined using the 
Legit-log plot (pseudo-Hill plot). The analogue-induced 
percentage of inhibition (P) of [3H]DA release evoked by 
S(—)nicotine (10 M) was used to calculate log (P/[1-P]), 
which Was plotted against the log concentration of analog. 
ICSO for each animal was determined as the intercept of the 
linear regression. For each analogue, the IC50 was obtained 
from the mean of the group of animals used for that 
analogue. Structures of the N-substituted compounds are 
given in FIG. 1. 
FIG. 3. Space ?lling models of minimum energy con 
formers of N'-protonated S(—)nicotine and the unprotonated 
and protonated forms of NONI. 
FIG. 4. Overlay of the minimum energy conformers of 
protonated S(—)nicotine (red) and unprotonated S(—)NONI 
(black) showing the comparable N-N intra-atomic distances 
in these molecules and the hypothetical mode of binding at 
the anionic site (A) and the hydrogen donor site (B) of the 
nicotinic receptor. 
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The purpose of the above description and examples is to 
illustrate some embodiments of the present invention with 
out implying any limitation. It will be apparent to those of 
skill in the art that various modi?cations and variations may 
be made to the composition and method of the present 
inven?on without departing from the spirit or scope of the 
invention. All patents and publications cited herein are 
incorporated by reference in their entireties. 
We claim: 
1. A compound of the following formula: 
| 
I / CH3 
“i 
Cl’h-R 
wherein R=branched alkyl with 4-19 carbon atoms, 
cycloalkyl, N-alkenyl or alkenyl with 4-19 carbon atoms, 
and N-alkynyl or branched alkynyl with 4-19 carbon atoms; 
and X=Cl*, 1“, H804“, $68042“. 
2. A compound according to claim 1, wherein in R is 
branched alkyl with 4-19 carbon atoms. 
3. A compound according to claim 1, wherein in X is I‘. 
4. A compound according to claim 1, wherein said com 
pound is selected from the group consisting of S-N 
hydroxyethyl nicotinium iodide (NHENI), S-N-propyl nico 
tinium iodide (NPNI), S-N-benzyl nicotinium bromide 
(NBNB), S-N-octylnicotinium iodide (NONI), and S-N 
allyl-nicotinium iodide (NANI). 
5. A compound according to claim 4, wherein said com 
pound has an order of potency wherein 
NONI>>MEC>>NPNI=NANI>NHENI>>>(i)di-N-allyl 
nicotinium iodide (DNANI)=(i)N-methyl nornicotinium 
iodide (NMNNI)=NMNI= S-N-methyl cotininium iodide 
(NMCI)=S-N'-methy1 nicotinium iodide PIPNMN). 
6. A compound according to claim 1, wherein said com 
pound is a nicotinic receptor antagonist. 
7. A compound according to claim 1, wherein said com 
pound inhibits nicotine-evoked dopamine release. 
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8. A method of antagonizing the nicotinic receptor com 
prising administering a pharmaceutically c?’ective amount 
of a compound according to the following formula: 
Xe 
CHg-R 
wherein R=N-alkyl or branched alkyl with 2-19 carbon 
atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19 
carbon atoms, and N -alkynyl or branched alkynyl with 2-19 
carbon atoms; and X=Cl", Br‘, I“, H804‘, ‘AS042- to a host 
in need of said treatment. 
9. A method of treatment of a condition selected from the 
group consisting of abuse of nicotinic agonist drugs, smok 
ing addiction, and nicotine intoxication comprising admin 
istering a pharmaceutically e?tective amount of a compound 
according to the following formula: 
| | 
/ CH: 
*1 
CHz-R 
wherein R=N-alkyl or branched alkyl with 2-19 carbon 
atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19 
carbon atoms, and N-alkynyl or branched alkynyl with 2-19 
carbon atoms; and X=Cl_, Br‘, 1“, H804‘, VzSO42' to a host 
in need of said treatment. 
10. A method of treatment of Alzheimer’s disease com 
prising administering a pharmaceutically e?ective amount 
of a compound of the following formula: 
wherein R=N-a1kyl or branched alkyl with 2-19 carbon 
atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19 
carbon atoms, and N-alkynyl or branched alkynyl with 2-19 
carbon atoms; and X=Cl_, Br‘, I‘, H804“, 1/2SO42_ to a host 
in need of said treatment. 
11. A compound according to claim 1 wherein said 
compound competitively inhibits central nervous system 
acting nicotinic agonists. 
12. A compound according to claim 11 wherein said 
compound acts at the (13152 neuronal nicotinic receptor in the 
central nervous system. 
13. A method of treatment of Parkinson=’s disease com 
prising administering a pharmaceutically effective amount 
of a compound according to the following formula: 
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wherein R=N-alkyl or branched alkyl with 2-19 carbon 
atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19 
4-19 carbon atoms, and N -a]kynyl or branched alkynyl with 
2-19 carbon atoms; and X=Cl_, Br‘, 1“, H504‘, ‘AS042’ to 
a host in need of said treatment. 
